CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 216,802	$ 201,525
Related party receivables from collaborative arrangements	93,515	110,711
Prepaid expenses	5,576	1,367
Other current assets	1,930	70
Total current assets	317,823	313,673
Property and equipment, net	191	12
Equity and long-term investments	544,437	483,845
Capitalized fees paid to a related party, net	107,974	111,430
Right of use assets	3,794	97
Goodwill	5,544	0
Intangible assets	105,000	0
Deferred tax assets, net	22,398	17,327
Other assets	313	11
Total assets	1,107,474	926,395
Current liabilities:
Accounts payable	1,808	27
Accrued personnel-related expenses	1,933	619
Accrued interest payable	1,397	4,152
Convertible subordinated notes due 2023, net of issuance costs	96,016	0
Other accrued liabilities	8,073	1,009
Total current liabilities	109,227	5,807
Long-term debt, net of discount and issuance costs	442,731	394,653
Lease liabilities, long-term	3,299	0
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 69,594 and 69,566 issued and outstanding as of March 31, 2022 and December 31, 2021 respectively	696	696
Treasury stock: at cost, 32,005 at March 31, 2022 and December 31, 2021, respectively	(393,829)	(393,829)
Additional paid-in capital	1,182,912	1,264,024
Accumulated deficit	(403,137)	(456,148)
Total Innoviva stockholders' equity	386,642	414,743
Noncontrolling interest	165,575	111,192
Total stockholders' equity	552,217	525,935
Total liabilities and stockholders' equity	$ 1,107,474	$ 926,395